gvtcx

PHE - Corporate - A Clinical and Cost Effectiveness Model on Formalising New-born Screening for β-thalassaemia Major

Public Health England Published 3 Nov 2020 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Statuscomplete
Category (CPV) 75122000
Deadline14 Oct 2020
Contract start2 Nov 2020
Contract end29 Apr 2022
SME suitableYes
OCIDocds-b5fd17-c3bc1455-05fb-40aa-b60c-86a4e392e922

Award

SupplierValueDateStatus
Costello Medical Consulting Ltd £81,463 30 Oct 2020 active

description

Commissioning document: Formalising screening for β-thalassaemia major as part of the newborn blood spot screening programme for sickle cell disease: a clinical and cost-effectiveness model

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
3 Nov 2020 Award (award) · 5b40fcf5-b857-442f-a665-efa3f1317897-390886

more from Public Health England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.